Dana Ben-Ami Shor

Dr. Dana Ben-Ami Shor

Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2011 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
ALAaron Lerner
Aaron Lerner
YSYinon Shapira
Yinon Shapira
NANancy Agmon-Levin
Nancy Agmon-Levin
APAvi Pacht
Avi Pacht
Dana Ben-Ami ShorDana Ben-Ami Shor
Dana Ben-Ami Shor
YSYehuda Shoenfeld
Yehuda Shoenfeld

1 November 2016 in Autoimmunity Reviews
Verified
Journal Article
Closed access
Dana Ben-Ami ShorDana Ben-Ami Shor
Dana Ben-Ami Shor
SDShani Dahan
Shani Dahan
DCDoron Comaneshter
Doron Comaneshter
ACArnon D. Cohen
Arnon D. Cohen
HAHoward Amital
Howard Amital

1 September 2009 in Annals of the New York Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Dana Ben-Ami ShorDana Ben-Ami Shor
Dana Ben-Ami Shor
OBOri Barzilai
Ori Barzilai
MRMaya Ram
Maya Ram
DIDavid Izhaky
David Izhaky
BPBat Sheva Porat‐Katz
Bat Sheva Porat‐Katz
YSYehuda Shoenfeld
Yehuda Shoenfeld

26 December 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Dana Ben-Ami ShorDana Ben-Ami Shor
Dana Ben-Ami Shor
JLJordan Lachnish
Jordan Lachnish
TBTomer Bashi
Tomer Bashi
Shani DahanShani Dahan
Shani Dahan
ASAsaf Shemer
Asaf Shemer
Yehuda ShoenfeldYehuda Shoenfeld
Yehuda Shoenfeld
Helminths or their products can immunomodulate the host immune system, and this phenomenon may be applied as the basis of new anti-inflammatory treatments. Previously, we have shown the efficacy of tuftsin–phosphorylcholine (TPC), based on a helminth product, in four animal models of autoimmune diseases: arthritis, colitis, systemic lupus erythematosus, and experimental autoimmune encephalomyelitis. We demonstrated that TPC reduced inflammatory process ex vivo in peripheral blood lymphocytes (PBLs) and in biopsies from giant-cell arteritis. In the present study, we assessed the therapeutic potential of TPC treatment on a chronic colitis murine model. C57BL/6 mice with chronic colitis were treated with TPC after the third cycle of 2% dextran sodium sulfate (DSS). Oral TPC treatment resulted in amelioration of the colitis clinical manifestations exemplified by reduced disease activity index (DAI) score, expansion of mesenteric lymph nodes (MLN) T regulatory cells (shown by Fluorescence Activated Cell Sorting (FACS)), significant reduction in the expression of pro-inflammatory cytokines (IL-1β, IL17, IL-6, TNFα), and elevation in the expression of anti-inflammatory cytokine IL-10 (shown by RT-PCR). This study demonstrated the potential immunomodulatory effects of oral administration of TPC in a chronic colitis murine model. Further clinical trials are needed in order to evaluate this novel approach for the treatment of patients with inflammatory bowel disease.

25 May 2012
Verified
Journal Article
Closed access
Dana Ben-Ami ShorDana Ben-Ami Shor
Dana Ben-Ami Shor
HOHedi Orbach
Hedi Orbach
MBMona Boaz
Mona Boaz
AAArie Altman
Arie Altman
Juan-Manuel AnayaJuan-Manuel Anaya
Juan-Manuel Anaya
YSYehuda Shoenfeld
Yehuda Shoenfeld

Verified
Journal Article
Open access
PDF file
Dana Ben-Ami ShorDana Ben-Ami Shor
Dana Ben-Ami Shor
IHIlan Hochman
Ilan Hochman
NGNathan Gluck
Nathan Gluck
OSOren Shibolet
Oren Shibolet
ESErez Scapa
Erez Scapa
Purified cannabinoids have been shown to prevent proliferation and induce apoptosis in colorectal carcinoma cell lines. To assess the cytotoxic effect of cannabinoid extracts and purified cannabinoids on both colorectal polyps and normal colonic cells, as well as their synergistic interaction. Various blends were tested to identify the optimal synergistic effect. Methods: Biopsies from polyps and healthy colonic tissue were obtained from 22 patients undergoing colonic polypectomies. The toxicity of a variety of cannabinoid extracts and purified cannabinoids at different concentrations was evaluated. The synergistic effect of cannabinoids was calculated based on the cells’ survival. Isolated cannabinoids illustrated different toxic effects on the viability of cells derived from colorectal polyps. THC-d8 and THC-d9 were the most toxic and exhibited persistent toxicity in all the polyps tested. CBD was more toxic to polypoid cells in comparison to normal colonic cells at a concentration of 15 µM. The combinations of the cannabinoids CBDV, THCV, CBDVA, CBCA, and CBGA exhibited a synergistic inhibitory effect on the viability of cells derived from colon polyps of patients. Isolated cannabinoid compounds interacted synergistically against colonic polyps, and some also possessed a differential toxic effect on polyp and adjacent colonic tissue, suggesting possible future therapeutic value.